IMPAHCT Aerovate AV-101-002. IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24- Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH).

Administered By

Awarded By

Contributors

Start/End

  • March 2, 2022 - January 14, 2025